- Home
- OBIO vs KVAC Comparison
OBIO vs KVAC Comparison
Compare OBIO & KVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- KVAC
- Stock Information
- Founded
- OBIO 2017
- KVAC 2021
- Country
- OBIO United States
- KVAC United States
- Employees
- OBIO N/A
- KVAC N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- KVAC
- Sector
- OBIO Health Care
- KVAC
- Exchange
- OBIO Nasdaq
- KVAC Nasdaq
- Market Cap
- OBIO 198.2M
- KVAC 212.1M
- IPO Year
- OBIO N/A
- KVAC 2023
- Fundamental
- Price
- OBIO $4.72
- KVAC $11.13
- Analyst Decision
- OBIO Strong Buy
- KVAC
- Analyst Count
- OBIO 4
- KVAC 0
- Target Price
- OBIO $16.25
- KVAC N/A
- AVG Volume (30 Days)
- OBIO 50.3K
- KVAC 7.4K
- Earning Date
- OBIO 03-26-2025
- KVAC 01-01-0001
- Dividend Yield
- OBIO N/A
- KVAC N/A
- EPS Growth
- OBIO N/A
- KVAC N/A
- EPS
- OBIO N/A
- KVAC 0.43
- Revenue
- OBIO $2,647,000.00
- KVAC N/A
- Revenue This Year
- OBIO $22.61
- KVAC N/A
- Revenue Next Year
- OBIO $16.64
- KVAC N/A
- P/E Ratio
- OBIO N/A
- KVAC $25.80
- Revenue Growth
- OBIO N/A
- KVAC N/A
- 52 Week Low
- OBIO $3.96
- KVAC $10.39
- 52 Week High
- OBIO $8.87
- KVAC $11.14
- Technical
- Relative Strength Index (RSI)
- OBIO 38.59
- KVAC 69.43
- Support Level
- OBIO $5.20
- KVAC $11.10
- Resistance Level
- OBIO $5.98
- KVAC $11.14
- Average True Range (ATR)
- OBIO 0.42
- KVAC 0.00
- MACD
- OBIO -0.07
- KVAC -0.00
- Stochastic Oscillator
- OBIO 2.70
- KVAC 80.00
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.